Bio International Content hub
Turn Data Into Direction at BIO 2026
Get the independent data, forecasting and competitive context you need to walk into every meeting with confidence.
WHAT’S HAPPENING AT BIO
What to expect from Evaluate at BIO 2026
Evaluate Bio International digital magazine
Read the full BIO International 2026 special edition here.
Hear from Norstella and BIO on the state of emerging biotechs
The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
23rd June 1:45 PM –2:45 PDT
Breakout Session | Business Development and Investment | 29AB
Daniel Chancellor - VP, Thought Leadership, Norstella
Chad Wessel, Senior Director, Emerging Companies Strategic Initiatives, BIO
Join Dan Chancellor and Chad Wessel for a data-driven session exploring the state of play for emerging biotech companies.
The session will examine venture capital and public financing trends, dealmaking activity and the dynamics shaping the R&D pipeline. With emerging biotechs navigating continued market pressure and new sources of competition, the discussion will focus on the signals that matter as companies reach value inflection points, seek investment and work to bring novel therapies closer to patients.
For anyone tracking biotech innovation, investment activity, partnering strategy or pipeline momentum, this session will offer a timely view of the forces shaping the emerging biotech ecosystem.
Launching at BIO: World Preview 2026
The World Preview is Evaluate’s annual outlook on the future of pharma
This year’s report looks ahead to 2032, combining Evaluate’s trusted forecast data with expert analysis on the companies, products, therapy areas and market forces expected to shape the next phase of industry growth.
Pick up your executive summary at Booth 4819 and download the full report for a deeper view of the biopharma market through 2032.
Inside the report, we’ll explore:
- The top 10 companies and drugs by forecast sales
- Market growth across the industry and by therapy area
- 500bn at risk from the patent cliff behind the patent cliff
- Top products by net present value
- The key themes set to define the next five years in biopharma, including China and changing payer priorities
Worldwide Total Prescription Drug Sales (2018 -2032)
Historical (2018-2025)
Forecast (2026-2032)
WW Prescription Drug Sales ($bn)
See the new Evaluate Pharma experience
We’ll also be showcasing the new Evaluate Pharma experience at BIO.
Designed to help teams get from question to insight faster, the new experience brings clearer workflows, smarter search, stronger reporting, and more intuitive navigation into one streamlined platform.
With the new Evaluate Pharma experience, you can:
- Move from question to insight with less effort
- Find what you need without digging
- Create cleaner, more actionable reports
- Build presentation-ready visualizations directly in-platform
- Reduce offline data manipulation
- Spend more time analyzing and less time reworking data
For many teams, this means less reliance on power users, faster answers to day-to-day questions, and more confidence in the data behind critical decisions.
Explore the Evaluate solutions being showcased at BIO
Evaluate helps teams across the biopharma ecosystem bring more clarity to those conversations. Whether you are assessing a market opportunity, validating an investment case, mapping the competitive landscape, preparing for a partnering meeting, or building a commercial strategy, our data and expertise help you move forward with confidence.
Forecasting
Empower your organization with a suite of forecasting tools designed to enhance decision-making and refine your commercial strategy.
Discover >
Business Development & Licensing
Streamline your business development and licensing strategies with solutions that provide the insight you need to make informed partnering decision.
Discover >
Portfolio Strategy
Enhance asset management with powerful tools that enable data-driven decisions and optimize your portfolio strategy for sustainable growth.
Discover >
Competitive Intelligence
Monitor market trends, anticipate competitor actions, and make strategic, data-driven decisions that will enhance your position in the competitive landscape.
Discover >
Use Cases
How Evaluate Helps
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Asset Screening
Benchmark Internal Forecasts with Consensus Forecasts
Screen and validate potential in‑licensing or acquisition assets by comparing internal views with trusted consensus forecasts to spot positive signals and red flags.
Focus on Specific Business Questions
Use the NPV Analyzer to project sales, peak revenue, and costs, identifying risks and opportunities to generate actionable recommendations.
Build and Inform Your Investment Strategy
Analyze markets, macrotrends, and companies to identify funding or acquisition targets early, assessing R&D risk and return from a single integrated view.
Company Profiling
Find Opportunities That Align With Your Strategy
Identify companies that match your objectives by evaluating their financials, strategic direction, and key upcoming milestones.
Track And Manage Your Targets
Build and manage target lists while assessing partnership openness and comparing phase‑level assets against competitors.
Defend And Validate Your Assumptions
Use robust tools and audited data to identify opportunities, reduce portfolio risk, and refine company profiles to maximize ROI.
Deal Benchmarking
Leverage Accurate Forecasts
Use transparent analyst‑driven forecasts and historical comparables to guide strategy, identify acquisition opportunities, and structure smarter deals.
Create Custom Benchmarks And Validate Internal Valuations
Benchmark competitor deal terms, including upfronts, milestones, and royalties—to validate internal valuations and understand true asset value.
Optimize Existing Workflows
Compare key metrics, validate assumptions, and streamline decisions using tailored intelligence powered by intuitive search and filtering.
Ready to see how Evaluate can help you make smarter decisions?
Get in touch with our team to explore the right solutions for your business.
Frequently Asked Questions
Where can I find Evaluate at BIO International 2026?
You can find Evaluate at Booth 4819 at BIO International 2026. Visit the booth to meet the team, explore our latest insights, see the new Evaluate Pharma experience, and discuss how our data and expertise can support your strategic decisions
Can I book a meeting with Evaluate at BIO?
Yes. You can book a meeting with the Evaluate team in advance to discuss your goals, explore relevant workflows, prepare for key BIO conversations, or understand how Evaluate can support your market, investment, partnering, or commercial strategy.
Can Evaluate help with valuation and scenario planning?
Evaluate will be launching World Preview 2026 at BIO International. The report provides a forward-looking view of the biopharma market through 2032, covering forecast sales, leading companies and products, therapy area growth, loss of exclusivity risk, and key industry themes.
What is the new Evaluate Pharma experience?
The new Evaluate Pharma experience is designed to help teams move from question to insight faster, with clearer workflows, smarter search, stronger reporting, more intuitive navigation, and presentation-ready visualizations.
Will Evaluate be speaking at BIO International 2026?
Yes. Dan Chancellor, VP Thought Leadership at Norstella, will join Chad Wessel, Senior Director, Emerging Companies Strategic Initiatives at BIO, for a session on the state of emerging biotechs, including investment, dealmaking, and pipeline trends.
